Abstract:[Background] The WNT/β-catenin signaling pathway is a major oncogenic pathway of human hepatocellular carcinoma (HCC). More than 50% of HCCs have aberrant activation of WNT/β-catenin signaling, which are caused by genetic alterations, ligand activation, or cross-activation by other signaling pathways. We hypothesized that activating mutation of CTNNB1, the coding gene of β-catenin, may confer sensitivity to WNT/β-catenin inhibitors in HCC cells. [Materials and Methods] SNU398 is a human HCC cell line harboring a missense somatic mutation in exon 3 of CTNNB1 gene, resulting in S37C mutation. Huh7, HepG2, PLC5, and Hep3B are HCC cells containing no somatic mutations in exon 3 of CTNNB1 gene. HCC cells were treated with various types of WNT/β-catenin pathway inhibitors, including ICG-001 which down-regulates β-catenin/TCF transcriptional activity by interfering the binding of β-catenin with its transcriptional activation complex, XAV939 which targets tankyrases and facilitates degradation of β-catenin, and LGK974 which inhibits Porcupine, an acyltransferase responsible for palmitoylation and secretion of Wnt ligands, and evaluated for in vitro viability by MTT. [Results] ICG-001 as a single agent showed significantly greater anti-proliferation effect in SNU398 than other HCC cells. The 50%-inhibitory concentrations (IC50s) of ICG-001 were 5 μM and >10 μM for SNU398 and other HCC cells, respectively. ICG-001 also induced a more potent suppression of colony- formation, and a more significant increase of subG1 fraction detected by flow cytometry in SNU398 cell than other HCC cells. XAV939 up to 20 μM induced only modest anti-proliferative effect in all HCC cells. However, SNU398 remained the one showing the greatest sensitivity to the growth suppression induced by XAV939. The anti-proliferative effect of LGK974 was modest and showed no significant difference among different HCC cells. [Conclusion] The activating mutation of β-catenin may confer sensitivity to certain WNT/β-catenin pathway inhibitors, such as ICG-001, in HCC cells. (This study was supported by grants NRPB-100CAP1020-2). Citation Format: Hsiao-Hui Lin, Wen-Chi Feng, LI-Chun Lu, Ta-Wen Hsu, Ann-Lii Cheng, Chih-Hung Hsu. Increased sensitivity to Wnt/beta-catenin inhibitors in hepatocellular carcinoma cells harboring activating mutation of beta-catenin. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2625. doi:10.1158/1538-7445.AM2014-2625

Erratum: LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction (LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction (2013) 5(6) (1650–1663), (S2211124713007213), (10.1016/j.celrep.2013.11.037))

Cell type-dependent function of LATS1/2 in cancer cell growth

Lats2, a Putative Tumor Suppressor, Inhibits G1/S Transition

T851I Mutation of Human Large Tumor Suppressor 1 Disrupts Its Kinase Activity and Tumor-Suppressor Functions.

LATS2 Inhibits the Activity of NF-κ B Signaling by Disrupting the Interaction Between TAK1 and IKKβ

LATS1 tumor suppressor regulates G2/M transition and apoptosis

SUMOylation of Large Tumor Suppressor 1 at Lys751 Attenuates Its Kinase Activity and Tumor-Suppressor Functions

Putative Tumor Suppressor Lats2 Induces Apoptosis Through Downregulation of Bcl-2 and Bcl-x(L).

LCAT1 is an Oncogenic LncRNA by Stabilizing the IGF2BP2-CDC6 Axis

LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

LATS2 induced by TNF-alpha and inhibited cell proliferation and invasion by phosphorylating YAP in oral squamous cell carcinoma.

Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Down-regulation of LATS2 in Non-Small Cell Lung Cancer Promoted the Growth and Motility of Cancer Cells

LATS1 K751 Acetylation Blocks Activation of Hippo Signalling and Switches LATS1 from a Tumor Suppressor to an Oncoprotein

LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP

Increased Sensitivity To Wnt/Beta-Catenin Inhibitors In Hepatocellular Carcinoma Cells Harboring Activating Mutation Of Beta-Catenin

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development